# Bias and Confounding in CRISPR Screening Experiments

## Quick Answer

- Design CRISPR screens with biological and technical replicates to distinguish true genetic effects from noise and batch variation.
- Validate candidate hits with independent assays, including orthogonal gene-editing methods and phenotypic confirmation.
- Interpret screen results cautiously because guide RNA efficiency, off-target activity, and cell line heterogeneity can produce false positives and false negatives.

## Understanding Bias and Confounding in CRISPR Screens

CRISPR screening is a powerful method for identifying genes that influence a phenotype of interest. The approach uses libraries of guide RNAs to introduce targeted mutations across a cell population, then measures which mutations become enriched or depleted under selective conditions. The output is a ranked list of candidate genes, but the path from raw sequencing counts to biological conclusion is full of potential distortions.

Bias refers to systematic errors that push results in a particular direction. Confounding occurs when an extraneous variable correlates with both the experimental condition and the outcome, making it difficult to attribute the observed effect to the intended cause. In CRISPR screens, both problems can arise from the molecular biology of the editing process itself, from the design of the guide RNA library, from the behavior of the cells being screened, and from the computational steps used to analyze the data.

A researcher planning a CRISPR screen needs to anticipate these issues before ordering a library or seeding cells. The decisions made at the design stage determine whether the screen will produce reliable hits or a list of artifacts that waste months of follow-up work. This article covers the main sources of bias and confounding in CRISPR screens, the practical steps to mitigate them, and the records and quality checks that support reproducible results.

## At a Glance

| Design Element | Purpose | Common Failure Mode |
| --- | --- | --- |
| Guide RNA library design | Target genes with multiple guides to control for guide-specific effects | Single-guide designs that cannot distinguish true gene effects from guide artifacts |
| Biological replicates | Capture natural variation between independent cell populations | Technical replicates that measure the same batch and miss batch effects |
| Control conditions | Provide a baseline for comparing enrichment and depletion | Missing or mismatched controls that make hit calling unreliable |
| Sequencing depth | Ensure enough reads to detect rare guides in the population | Insufficient depth that misses low-abundance guides and creates false negatives |
| Computational normalization | Adjust for library composition and sequencing variation | Over-normalization that removes real biological signal |

## Core Principles of Unbiased CRISPR Screening

### Guide RNA Efficiency as a Source of Bias

Guide RNA efficiency varies widely across the genome. Some guides cut their target site with high efficiency, while others show weak activity or fail to cut altogether. When a screen uses a single guide per gene, the measured phenotype is a mixture of the true gene effect and the guide-specific cutting efficiency. A gene with a strong biological effect but a weak guide can appear as a false negative, while a gene with no real effect but an unusually efficient guide can appear as a false positive.

The standard solution is to use multiple guides per gene, typically four to six in pooled libraries. This design allows the analysis to aggregate signal across guides and to flag genes where only one guide shows an effect, which is a warning sign of an off-target or guide-specific artifact. The tradeoff is that more guides per gene means fewer genes can be covered in a library of fixed size, so the researcher must balance coverage against the need for redundancy.

### Off-Target Effects and Their Consequences

Off-target activity occurs when a guide RNA binds to a genomic site that is not the intended target and induces a cut or other modification. The consequences of off-target activity depend on the experimental system. In a pooled screen, off-target cuts can produce phenotypes that are attributed to the wrong gene, creating false positives. In a therapeutic context, off-target activity raises safety concerns, but in a screening context the primary problem is the distortion of the hit list.

Several factors influence off-target risk. Guides with shorter seed regions are more likely to tolerate mismatches at the target site. Guides with high sequence similarity to other genomic locations have more potential off-target sites. The choice of nuclease also matters, as different Cas enzymes have different specificity profiles. The practical response is to select guides with validated specificity, to use a library that has been designed with off-target scoring, and to confirm candidate hits with independent methods.

### Cell Line Heterogeneity and Its Effects

Cell lines are not uniform populations. They contain subpopulations with different growth rates, different responses to selective pressure, and different genetic backgrounds. This heterogeneity can confound a screen in several ways. A subpopulation that grows faster under the selection condition will be enriched regardless of the guide it carries, creating false positives. A subpopulation that is more sensitive to the selection condition will be depleted, creating false negatives.

The practical response is to use a well-characterized cell line with a known karyotype and growth profile, to maintain consistent culture conditions across the experiment, and to include biological replicates that capture the variation between independent cell populations. The researcher should also consider the number of cells needed to maintain library coverage. If the library contains 100,000 guides and the researcher wants 500-fold coverage, the experiment needs 50 million cells at each time point, and the cell line must be able to grow to that scale without significant drift.

## Practical Workflow for Designing a CRISPR Screen

### Step 1: Define the Question and the Selection Condition

The first decision is the biological question. Is the screen looking for genes that are essential for survival, genes that confer resistance to a drug, genes that regulate a reporter, or genes that affect a specific pathway? The answer determines the selection condition, the duration of the experiment, and the type of analysis that will be used.

The selection condition must be designed to produce a measurable difference between the cells that carry the mutation and the cells that do not. A condition that is too weak will not separate the populations, and a condition that is too strong will kill everything. The researcher should run a pilot experiment to determine the appropriate dose and duration of the selection before committing to the full screen.

### Step 2: Choose the Library and the Control

The library is the set of guide RNAs that will be introduced into the cells. The choice of library depends on the genome of interest, the number of genes to be covered, and the number of guides per gene. The library should include a set of control guides that target genes with no known role in the phenotype of interest, as well as guides that target essential genes to confirm that the screen is working.

The control system is the set of cells that will be used as the baseline for comparison. The most common design is to compare the guide representation in the selected population against the guide representation in the input population. This comparison requires that the input population is sampled at the time of the experiment, not at the time of the library construction, because the library composition can change during the initial cell culture.

### Step 3: Determine the Scale and the Replicates

The scale of the experiment is determined by the number of guides in the library and the desired coverage. The coverage is the average number of cells that carry each guide. Higher coverage reduces the noise in the measurement but requires more cells and more sequencing. The researcher should also decide on the number of biological replicates, which are independent cell populations that are treated in parallel, and the number of technical replicates, which are repeated measurements of the same population.

The minimum number of replicates depends on the expected effect size and the variability of the system. A screen with a strong selection and a large effect size can be done with fewer replicates, while a screen with a subtle effect will need more. The researcher should consult the statistical literature on power analysis for CRISPR screens and should plan for the possibility of dropping a replicate if it fails quality control.

### Step 4: Perform the Screen and Collect the Samples

The screen itself involves transducing the cells with the library, applying the selection condition, and collecting the cells at the appropriate time points. The cells are then lysed, the genomic DNA is extracted, and the guide RNA sequences are amplified by PCR and sequenced. The sequencing depth must be sufficient to cover the library at the same coverage as the cell population, otherwise the analysis will be limited by the sequencing noise.

The collection of the DNA is a critical step. The cells must be lysed in a way that preserves the guide RNA sequences, and the PCR amplification must be done with enough cycles to produce a sufficient amount of DNA but not so many cycles that the amplification introduces bias. The PCR primers must include the sequencing adapters and the barcodes that allow the samples to be pooled and then separated during the analysis.

### Step 5: Analyze the Data and Rank the Hits

The analysis begins with the sequencing reads, which are aligned to the guide RNA library to produce a count for each guide. The counts are then normalized to account for the total number of reads in each sample, and the fold change between the selected and the control samples is calculated for each guide. The fold changes are then aggregated across the guides for each gene, and the genes are ranked by the strength and the consistency of the effect.

The analysis must account for the fact that the guides for a gene are not independent. A gene with a strong effect will show a consistent change across all of its guides, while a gene with a weak effect will show a change in only some of the guides. The analysis should use a statistical model that accounts for this structure, such as a mixed-effects model or a model that uses the guide-level variance to estimate the gene-level effect.

## Options and Tradeoffs in CRISPR Screen Design

### Pooled versus Arrayed Screens

Pooled screens are the most common format for CRISPR screens. The library is delivered as a pool, and the cells are cultured together. The advantage is the scale, as a pooled screen can cover the entire genome in a single experiment. The disadvantage is that the readout is limited to the enrichment or depletion of the guides, which is a proxy for the phenotype. The screen cannot directly measure the phenotype of individual cells.

Arrayed screens are performed in a well-by-well format, with each well containing a single guide or a single gene knockout. The advantage is that the phenotype can be measured directly in each well, which allows for more complex readouts such as cell morphology, protein expression, or cell migration. The disadvantage is the scale, as an arrayed screen requires automation and is limited to a few thousand genes.

The choice between pooled and arrayed depends on the question. A pooled screen is appropriate for a survival or proliferation screen, where the readout is the growth of the cells. An arrayed screen is appropriate for a screen that requires a direct measurement of the phenotype, such as a screen for genes that regulate the expression of a specific protein.

### CRISPR Knockout versus CRISPR Interference and CRISPR Activation

CRISPR knockout introduces a permanent mutation that disrupts the gene. The effect is complete, but the mutation is not reversible, and the cell may compensate for the loss of the gene. CRISPR interference uses a catalytically dead Cas protein to block transcription of the gene, which reduces the expression but does not eliminate it. CRISPR activation uses a dead Cas protein fused to a transcriptional activator to increase the expression of the gene.

The choice between these systems depends on the biology of the gene. A gene that is essential for cell survival cannot be studied with a knockout, because the cells will die, and the screen will not be able to detect the effect. A CRISPR interference screen can reduce the expression of the gene to a level that is compatible with cell survival, which allows the screen to detect the effect. A CRISPR activation screen is used to identify genes that can promote a phenotype when overexpressed.

The tradeoff is that the CRISPR interference and CRISPR activation systems are more complex to deliver and to validate. The dead Cas9 must be expressed in the cells, and the guide RNA must be designed to target the promoter region of the gene instead of the coding region. The effect of the guide is also more variable, because the degree of the knockdown or the activation depends on the position of the guide relative to the transcription start site.

## Observations and Measurements

### Measuring Guide Representation

The primary measurement in a CRISPR screen is the representation of each guide in the cell population. This is measured by sequencing the guide RNA sequences that are present in the genomic DNA of the cells. The sequencing produces a count for each guide, and the count is proportional to the number of cells that carry that guide.

The quality of the measurement depends on the depth of the sequencing. The sequencing depth must be sufficient to cover the library at the same coverage as the cell population. If the library has 1000 guides and the cell population has 1000 cells per guide, the sequencing must produce at least 1 million reads per sample. The researcher should sequence to a depth that is at least the number of cells in the sample, and ideally higher, to account for the variation in the sequencing.

The measurement is also affected by the PCR amplification step. The PCR can introduce bias if the primers bind to the guide sequences with different efficiencies, or if the amplification is not uniform across the library. The researcher should use a PCR protocol that has been validated for the library, and should include a control that is the library itself, without the cell culture, to measure the PCR bias.

### Measuring the Effect Size

The effect size is the magnitude of the change in the representation of a guide between the selected and the control samples. The effect size is calculated as the log2 fold change, which is the logarithm of the ratio of the counts in the two samples. A positive fold change indicates that the guide is enriched in the selected sample, and a negative fold change indicates that the guide is depleted.

The effect size is the basis for the ranking of the genes. The genes are ranked by the magnitude of the effect, and the significance is calculated using a statistical test that accounts for the variance between the guides. The researcher should report the effect size and the significance for each gene, and should include the confidence intervals to indicate the uncertainty of the estimate.

### Measuring the Variability

The variability of the screen is the amount of variation that is not explained by the biological effect. The variability comes from the cell culture, the PCR, the sequencing, and the analysis. The researcher should measure the variability by comparing the replicates. The correlation between the replicates is a measure of the reproducibility of the screen, and the variance between the replicates is a measure of the noise.

The variability should be reported in the results, and the researcher should use the variability to determine the threshold for the hits. A gene with a large effect but a high variability may not be a reliable hit, while a gene with a small effect but a low variability may be a reliable hit. The researcher should use a statistical model that accounts for the variability, and should report the false discovery rate for the hits.

## Records and Measurements

### Documentation of the Screen Design

The first record is the design of the screen. This includes the library name and version, the number of guides per gene, the number of genes in the library, and the control guides. The record should also include the cell line, the passage number, and the culture conditions. The record should be detailed enough that another researcher can reproduce the screen.

The design record should also include the selection condition, the dose and the duration of the treatment, and the time points for the collection of the cells. The record should include the number of cells at each time point, and the coverage of the library at each time point. The record should include the number of replicates and the number of the samples.

### Documentation of the Screen Execution

The execution record should include the date and the time of each step, the person who performed the step, and the equipment that was used. The record should include the number of cells that were transduced, the number of cells that were selected, and the number of cells that were collected. The record should include the volume of the media, the concentration of the drug, and the duration of the selection.

The execution record should also include the quality control measurements. The researcher should measure the transduction efficiency, which is the percentage of cells that received the library. The researcher should measure the cell viability, which is the percentage of cells that survived the selection. The researcher should measure the DNA yield, which is the amount of DNA that was extracted from the cells.

### The Analysis Record

The analysis record should include the software and the version that was used for the analysis, the parameters that were used, and the date of the analysis. The record should include the number of reads that were generated, the number of reads that were aligned, and the number of reads that were discarded. The record should include the normalization method, the statistical model, and the threshold for the significance.

The analysis record should also include the results. The record should include the list of the hits, the effect size, the significance, and the false discovery rate. The record should include the plots and the tables that were generated, and the interpretation of the results.

## Common Failure Patterns

### The Failure of the Guide Efficiency

The most common failure pattern is the guide efficiency. A guide that does not cut the target gene will not produce a phenotype, and the gene will be missed in the screen. The failure is detected by the lack of a consistent effect across the guides for the gene. If the gene has four guides and only one shows an effect, the effect is likely due to the guide, not the gene.

The response is to design the library with multiple guides per gene, and to use a library that has been validated for the efficiency of the guides. The researcher should also include a control that is a gene that is known to be essential for the phenotype, and the control should show a consistent effect across all of its guides.

### The Off-Target Effect

The off-target effect is the second most common pattern. The guide cuts a site that is not the intended target, and the effect is due to the off-target cut, not the gene. The off-target effect is detected by the inconsistency of the effect across the guides for the gene, and by the presence of the effect in the control guides that are not expected to have an effect.

The response is to use a library that has been designed to minimize the off-target activity, and to confirm the hits with an independent method. The independent method can be a second library that uses different guides for the same gene, or a rescue experiment that expresses the gene in the knockout cells.

### The Cell Line Drift

The cell line drift is the third common pattern. The cell line changes over time, and the change affects the results of the screen. The drift is detected by the inconsistency of the results between the replicates, and by the change in the results over time. The drift is caused by the accumulation of the mutations in the cell line, the change in the culture conditions, or the selection of the subpopulation.

The response is to use a cell line that is well-characterized, to maintain the cell line under the same conditions, and to use the replicates that are performed at the same time. The researcher should also use a control that is a cell line that is known to be stable, and should compare the results of the screen to the results of the control.

## Limitations and Interpretation

### The Limits of the Screen

The CRISPR screen is a tool for the discovery of the candidate genes, not a tool for the confirmation of the effect. The screen produces a list of the genes that are enriched or depleted, but the list is not the final answer. The hits must be validated with independent methods, and the mechanism must be confirmed with the follow-up experiments.

The screen is also limited by the biology of the cell line. The cell line is a model, and the results may not be the same in the primary cells or in the in vivo system. The researcher should be aware of the limitations of the model, and should interpret the results in the context of the model.

### The Limits of the Analysis

The analysis is limited by the statistical power of the screen. The power is the ability to detect the effect, and the power is determined by the number of the guides, the number of the replicates, and the variability of the screen. The researcher should calculate the power before the screen, and should design the screen to have the power to detect the effect of interest.

The analysis is also limited by the assumptions of the statistical model. The model assumes that the guides are independent, that the effect is the same across the guides, and that the variability is the same across the guides. The assumptions may not be true, and the researcher should check the assumptions and use a model that is robust to the violations.

## Safety and Regulatory Context

### Biosafety in CRISPR Experiments

CRISPR experiments involve the use of the viral vectors, the cell lines, and the genetic modifications. The researcher should follow the biosafety guidelines of the institution, and should use the appropriate containment for the viral vectors and the cell lines. The researcher should also be aware of the regulations for the use of the genetic modifications, and should obtain the approval of the institutional biosafety committee before starting the experiment.

The researcher should also be aware of the safety of the reagents. The CRISPR enzymes and the guide RNAs are not hazardous, but the viral vectors can be hazardous if they are not handled properly. The researcher should use the appropriate personal protective equipment, and should follow the protocols for the handling of the viral vectors.

### Data Management and Sharing

The data from the CRISPR screen should be managed and shared according to the policies of the funding agency and the institution. The [NIH Data Management and Sharing Policy](https://sharing.nih.gov/data-management-and-sharing-policy) requires that the data from the NIH-funded research be shared in a repository that is appropriate for the data. The researcher should plan for the data sharing at the beginning of the project, and should include the data sharing plan in the grant application.

The data should be documented in a way that allows the other researchers to understand and to reproduce the analysis. The data should include the raw sequencing reads, the counts of the guides, and the results of the analysis. The data should be deposited in a repository that is appropriate for the data, and the repository should provide a persistent identifier for the data.

## Professional Escalation Criteria

The researcher should escalate the issue to the supervisor or the collaborator when the screen fails the quality control, when the results are inconsistent, or when the analysis is not clear. The escalation should include the documentation of the issue, the possible causes, and the proposed solution.

The researcher should also escalate the issue when the screen produces a result that is not expected, when the result is not reproducible, or when the result is not consistent with the literature. The escalation should include the data, the analysis, and the interpretation of the result.

The researcher should escalate the issue when the screen involves a new cell line, a new library, or a new selection condition. The escalation should include the validation of the new system, and the comparison of the new system to the known system.

## Decision Framework for Choosing Between Hit Validation Strategies

### The Validation Bottleneck Problem

A CRISPR screen typically produces dozens to hundreds of candidate hits, but the resources available for follow-up experiments are almost always limited. The researcher must decide which hits to validate first, which validation method to use for each hit, and how much evidence is sufficient before committing to mechanistic studies. Without a structured decision framework, the natural tendency is to validate the hits with the largest effect sizes, which can bias the follow-up toward genes with the strongest guide activity instead of the strongest biological relevance.

The decision framework described here separates the validation process into three stages: triage, orthogonal confirmation, and functional prioritization. Each stage uses different data from the screen and different experimental approaches. The framework is designed to be applied before the screen begins, so that the necessary samples and controls are collected at the right time.

### Stage 1: Triage Based on Guide-Level Consistency

The first stage uses the existing screen data to rank the hits by the strength of the evidence, beyond by the magnitude of the effect. The triage begins with the guide-level counts for each candidate gene. A gene with four guides that all show a consistent direction of change is a stronger candidate than a gene with four guides where only two show a change and two show no change.

The triage score combines three measurements. The first is the median log2 fold change across the guides for the gene. The second is the consistency score, which is the proportion of guides that show a change in the same direction. The third is the guide-level significance, which is the number of guides that pass the statistical threshold individually. A gene that scores high on all three measurements is a primary candidate. A gene that scores high on the median fold change but low on the consistency is a secondary candidate that requires additional scrutiny.

The triage should also include a check for the guide-level outliers. A gene where one guide shows a very large effect and the other guides show no effect is a warning sign of an off-target artifact. The researcher should flag this gene for a different validation approach, such as a second library with different guides, instead of a direct repeat of the same experiment.

### Stage 2: Validation Method Selection

The validation method depends on the biology of the gene and the type of screen. The decision tree has three branches.

The first branch is for genes that are essential for cell survival. These genes cannot be validated with a knockout approach because the cells will die. The validation should use CRISPR interference to reduce the expression of the gene, or a conditional knockout system that allows the gene to be turned off after the cells have been expanded. The validation should measure the same phenotype as the screen, and the result should show a consistent effect across multiple independent guide RNAs.

The second branch is for genes that are not essential but show a strong effect in the screen. The validation uses a second CRISPR library with different guide RNAs for the same gene. The second library should be designed with guides that target different regions of the gene, so that the validation is not confounded by the same off-target sites. The validation is successful if the gene shows a consistent effect across the two libraries.

The third branch is for genes that are flagged as potential off-target artifacts. The validation uses a rescue experiment, where the wild-type gene is expressed in the knockout cells. If the phenotype is rescued by the expression of the gene, the effect is due to the gene. If the phenotype is not rescued, the effect is likely due to an off-target cut. The rescue experiment is the most definitive validation, but it is also the most time-consuming and should be reserved for the genes that are the most biologically interesting.

### Stage 3: Mechanistic Prioritization

The final stage is the prioritization of the validated hits for mechanistic studies. The prioritization uses the biological context of the screen. A hit that is a known member of the pathway of interest is a higher priority than a hit that has no known connection to the phenotype. A hit that is a druggable target is a higher priority than a hit that is not, if the goal of the project is to identify therapeutic targets.

The prioritization should also consider the reproducibility of the effect across the replicates. A hit that shows a consistent effect in all of the biological replicates is a higher priority than a hit that shows an effect in only one replicate. The prioritization should be recorded in the analysis record, and the rationale for the prioritization should be documented so that the decisions can be reviewed.

### The Decision Record

The decision framework requires a record that is separate from the screen execution record. The decision record should include the list of the hits, the triage scores for each hit, the validation method that was selected, the date of the validation, and the outcome of the validation. The record should also include the rationale for the prioritization, and the final list of the genes that were selected for the mechanistic studies.

The decision record serves two purposes. The first is to ensure that the validation is complete and that no hits are lost. The second is to provide the evidence for the reporting of the results. The [EQUATOR Network](https://www.equator-network.org/) provides a list of the reporting guidelines that can be used to structure the reporting of the screen and the validation. The researcher should select the appropriate guideline at the beginning of the project and should use the guideline to structure the decision record.

### Common Failure Patterns in the Validation

The most common failure pattern is the validation that does not reproduce the screen result. The failure can be caused by the difference between the screen and the validation conditions. The screen uses a pooled population, while the validation uses a single clone or a small population. The difference can be due to the clonal variation, the difference in the selection pressure, or the difference in the time of the experiment.

The response is to document the conditions of the validation and to compare the conditions to the screen. The researcher should check the cell line, the passage number, the selection dose, and the duration of the experiment. The researcher should also check the guide RNA sequences to confirm that the validation uses the same guides as the screen.

The second failure pattern is the validation that is not reproducible. The validation is repeated and the results are different. The failure can be caused by the variability of the cell line, the variability of the assay, or the variability of the reagents. The response is to increase the number of the replicates in the validation and to use a statistical test that accounts for the variability.

The third failure pattern is the validation that is not specific. The validation shows an effect for the gene, but the effect is also seen in the control cells that do not have the gene knockout. The failure can be caused by the off-target activity of the guide, or by the effect of the transfection or the transduction on the cells. The response is to use a rescue experiment to confirm that the effect is due to the gene.

### Integration with the Reporting and the Publication Process

The decision framework produces a record that is the basis for the reporting of the results. The [Committee on Publication Ethics](https://publicationethics.org/core-practices) core practices require that the authors report the methods and the results in a way that is transparent and reproducible. The decision record should be included in the supplementary materials, and the rationale for the prioritization should be described in the methods section.

The researcher should also consider the authorship and the data management requirements of the funding agency. The [NIH Grants and Funding](https://grants.nih.gov/) pages describe the requirements for the grant applications and the award management. The [ORCID for Researchers](https://info.orcid.org/researchers) pages describe the requirements for the researcher identity and the record maintenance. The researcher should ensure that the decision record is associated with the researcher's ORCID record and that the data are deposited in a repository that is appropriate for the data.

The decision framework is a practical tool that can be applied to any CRISPR screen. The framework is designed to be flexible, and the researcher should adapt the framework to the specific question and the specific system. The framework is not a substitute for the scientific judgment, but it is a structure that ensures that the decisions are made in a consistent and a documented way.

## Frequently Asked Questions

### How many guides per gene should I use in a CRISPR screen?

Use at least four guides per gene in a pooled library. This design allows the analysis to average across the guides and to flag genes where only one guide shows an effect, which is a warning sign of a guide-specific or off-target effect. The trade-off is that more guides per gene means fewer genes can be covered in a library of fixed size.

### What is the difference between a biological replicate and a technical replicate in a CRISPR screen?

A biological replicate is an independent cell population that is cultured and processed in parallel. A technical replicate is a repeated measurement of the same cell population. Biological replicates capture the variation between cell populations, while technical replicates capture the variation in the measurement. Use biological replicates to estimate the variability of the screen.

### How do I know if my CRISPR screen has enough sequencing depth?

The sequencing depth should be at least the same as the number of cells in the library. If the library has 1000 guides and the cell population has 1000 cells per guide, the sequencing should produce at least 1 million reads per sample. Sequence to a depth that is higher than the cell number to account for the variation in the sequencing.

### What is the best control for a CRISPR screen?

The best control is a set of guides that target genes that are not expected to affect the phenotype of interest. The control should also include a set of guides that target genes that are known to be essential for the phenotype, to confirm that the screen is working. The control should be included in the library and should be analyzed in the same way as the test guides.

### How do I validate a hit from a CRISPR screen?

Validate a hit by using an independent method that does not rely on the same guide. Use a second CRISPR with different guides for the same gene, or use a targeted CRISPR to confirm the effect. The validation should also include a rescue experiment that expresses the gene in the cells to confirm that the effect is due to the gene.

### What is the false discovery rate in a CRISPR screen?

The false discovery rate is the expected proportion of the hits that are false positives. The rate is calculated by the statistical analysis, and the rate is controlled by the threshold for the significance. The researcher should report the false discovery rate for the hits, and should use a threshold that is appropriate for the screen.

### Can I use CRISPR interference instead of CRISPR knockout for my screen?

Yes, CRISPR interference is used to reduce the expression of a gene, and it is appropriate for genes that are essential for cell survival. CRISPR interference uses a dead Cas9 to block the transcription of the gene, and the effect is reversible. The trade-off is that the effect is more variable than the knockout, and the guide must be designed to target the promoter.

### What should I do if my screen fails the quality control?

If the screen fails the quality control, the first step is to document the failure and to identify the cause. The cause may be the library, the cell line, the selection condition, or the analysis. The next step is to correct the cause and to repeat the screen. The screen should be repeated with the same design and the same conditions, and the results should be compared to the results of the first screen.

## Using the Evidence

| Source | Best use in this topic | Important limitation |
|---|---|---|
| [Research Methods Resources](https://www.ncbi.nlm.nih.gov/books) | official guidance | Check the linked page for current local requirements |
| [EQUATOR Network](https://www.equator-network.org/) | official guidance | Check the linked page for current local requirements |
| [Core Practices](https://publicationethics.org/core-practices) | official guidance | Check the linked page for current local requirements |

## Related Diagnostic Guides

- [Sequencing Primer Design: Key Considerations for Reliable Results](/knowledge/diagnostics/molecular/sequencing-primer-design-key-considerations-for-reliable-results)
- [Gram-Positive vs Gram-Negative Cell Walls: A Comparative Guide](/knowledge/diagnostics/emerging-tech/gram-positive-vs-gram-negative-cell-walls-a-comparative-guide)
- [Animal Biology](/blog/guides/animal-biology)

## References and Further Reading

- [Research Methods Resources](https://www.ncbi.nlm.nih.gov/books). National Library of Medicine.
- [EQUATOR Network](https://www.equator-network.org/). EQUATOR Network.
- [Core Practices](https://publicationethics.org/core-practices). Committee on Publication Ethics.
- [NIH Grants and Funding](https://grants.nih.gov/). National Institutes of Health.
- [ORCID for Researchers](https://info.orcid.org/researchers). ORCID.
- [Data Management and Sharing Policy](https://sharing.nih.gov/data-management-and-sharing-policy). National Institutes of Health.
- [Laboratory Biosafety Manual](https://www.who.int/publications/i/item/9789240011311). World Health Organization.
- [NCBI Literature Resources](https://www.ncbi.nlm.nih.gov/). National Center for Biotechnology Information.
- [Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute.](https://pubmed.ncbi.nlm.nih.gov/30710114). Nature protocols, 2019.
- [Clusterin drives myeloid bias in aged hematopoietic stem cells by regulating mitochondrial function.](https://pubmed.ncbi.nlm.nih.gov/40588652). Nature aging, 2025.
- [Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming.](https://pubmed.ncbi.nlm.nih.gov/38519786). Nature cancer, 2024.

> This article is educational and does not replace validated laboratory procedures, institutional biosafety review, manufacturer instructions, or professional interpretation.